Skip to main content
. 2023 Oct 12;15(1):2261509. doi: 10.1080/19420862.2023.2261509

Figure 4.

Immunofluorescent images showing the localization of microglia, gantenerumab, vascular basement membrane and nuclei staining in cynomolgus cortex brain sections 24 h after a single IV injection of trontinemab or gantenerumab. At 24 h post-dose, gantenerumab is limited to vasculature, whereas trontinemab is present in the parenchyma in addition to vasculature.

Triplex immunofluorescence of cynomolgus cortex brain sections 24 hours after a single IV injection of trontinemab (top) or gantenerumab (bottom). Immunofluorescent images showing the localization of microglia (IBA1, red), therapeutic antibody (anti-idiotypic) (yellow), vascular basement membrane (collagen IV, green) and nuclei (DAPI, blue) staining in brain sections 24 hours after trontinemab or gantenerumab dosing. At 24 hours post-dose, gantenerumab is limited to vasculature (co-localization with collagen IV), whereas trontinemab is present in the parenchyma (IBA1 co-localization) in addition to vasculature. Immunostaining was performed using the Ventana Discovery Ultra automated stainer. DAPI, 4′,6-diamidino-2-phenylindole; IBA1, ionized calcium-binding adaptor protein.